D8.6 OPTIMAI commercialization and exploitation strategy

Deliverable D8.6 OPTIMAI commercialization and exploitation strategy 1 st version is the first version of the OPTIMAI Exploitation Plan. Exploitation aims at ensuring that OPTIMAI becomes sustainable well after the conclusion of the research project period so as to create impact. OPTIMAI intends to develop an industry environment that will optimize production, reducing production line scrap and production time, as well as improving the quality of the products through the use of a variety of technological solutions, such as Smart Instrumentation of sensors network at the shop floor, Metrology, Artificial Intelligence (AI), Digital Twins, Blockchain, and Decision Support via Augmented Reality (AR) interfaces. The innovative aspects: Decision Support Framework for Timely Notifications, Secure and adaptive multi-sensorial network and fog computing framework, Blockchain-enabled ecosystem for securing data exchange, Intelligent Marketplace for AI sharing and scrap re-use, Digital Twin for Simulation and Forecasting, Embedded Cybersecurity for IoT services, On-the-fly reconfiguration of production equipment allows businesses to reconsider quality management to eliminate faults, increase productivity, and reduce scrap. The OPTIMAI exploitation strategy has been drafted and it consists of three phases: Initial Phase, Mid Phase and Final Phase where different activities are carried out. The aim of the Initial phase (M1 to M12), reported in this deliverable, is to have an initial results' definition for OPTIMAI and the setup of the structures to be used during the project lifecycle. In this phase, also each partner's Individual Exploitation commitments and intentions are drafted, and a first analysis of the joint exploitation strategies is being presented. The next steps, leveraging on the outcomes of the preliminary market analysis, will be to update the Key Exploitable Results with a focus on their market value and business potential and to consolidate the IPR Assessment and set up a concrete Exploitation Plan. The result of the next period of activities will be reported in D8.7 OPTIMAI commercialization and exploitation strategy - 2nd version due at month 18 (June 2022

Synergistic effects of fumonisin B1 and ochratoxin A : are in vitro cytotoxicity data predictive of in vivo acute toxicity ?

International audienceContamination of food and feeds by mycotoxins is a major problem of human and animals health concern which is also extremely detrimental to economy. Mycotoxins producing moulds may produce a diversity of toxins such as aflatoxins, ochratoxins, trichothecenes, zearalenone, fumonisins, tremorgenic toxins and ergot alkaloids. Although toxicological, environmental and epidemiological studies have addressed the problem of these toxins one by one, more than one mycotoxin are found usually in the same contaminated commodities. That rises the incommensurable problem of multi-toxicosis in which the respective metabolites are also involved. These mycotoxins bear potential toxicity leading to acute and chronic effects in humans and animals, depending on species. The mechanisms that lead to toxic effects, such as immune toxicity, and carcinogenicity are complexe. The risk assessment for humans potentially exposed to multi-mycotoxins suffers very much from the lack of adequate food consumption data. Furthermore, for a given mycotoxin synergism and antagonism with other mycotoxins found in the same food commodities are not taken into account. The case of combination of ochratoxin A (OTA) and fumonisin B1 (FB1) has been addressed in the present paper with the purpose of predicting the in vivo toxicity using a simple in vitro test, i.e. neutral red uptake, in three different cell-lines, C6 glioma cells, Caco-2 cells and Vero cells. Using the equation of [ATLA 27 (1999) 957], in vivo toxicity (LD50) is in adequation with the in vitro data, (IC50 values) for both toxins as well as for the combination of 10 microM OTA and variable concentrations of FB1 (10-50 microM). A synergistic effect is prouved in vitro that is in line with some in vivo data from the literature. Such simple in vitro test may thus help predicting in vivo toxicity of combinations of mycotoxins naturally occurring in foodstuffs

Obstructive Sleep Apnea, Hypertension, and Their Additive Effects on Atherosclerosis

Background and Aims. It is widely accepted that obstructive sleep apnea (OSA) is independently associated with atherosclerosis. Similar to OSA, hypertension (HTN) is a condition associated with atherosclerosis. However, to date, the impact of the simultaneous presence of OSA and HTN on the risk of atherosclerosis has not been extensively studied. The aim of this study was to evaluate the consequences of the coexistence of OSA and HTN on carotid intima-media thickness (IMT) and on inflammatory markers of atherosclerosis (such as interleukin- [IL-] 6 and pentraxin- [PTX-] 3). Methods. The study design allowed us to define 4 groups: (1) controls (n=30); (2) OSA patients without HTN (n=30); (3) HTN patients without OSA (n=30); (4) patients with OSA and HTN (n=30). In the morning after portable monitoring (between 7 am and 8 am), blood samples were collected, and carotid IMT was measured. Results. Carotid IMT, IL-6, and PTX-3 in OSA normotensive patients and in non-OSA HTN subjects were significantly higher compared to control subjects; in addition, in OSA hypertensive patients they were significantly increased compared to OSA normotensive, non-OSA HTN, or control subjects. Conclusions. OSA and HTN have an additive role in the progression of carotid atherosclerosis and in blood levels of inflammatory markers for atherosclerosis, such as interleukin-6 and pentraxin-3

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review

The optimal therapeutic strategy for locally advanced pancreatic cancer patients (LAPC) has not yet been established. Our aim is to evaluate how surgery after neoadjuvant treatment with either FOLFIRINOX (FFN) or Gemcitabine-NabPaclitaxel (GemNab) affects the clinical outcome in these patients. LAPC patients treated at our institution were retrospectively analysed to reach this goal. The group characteristics were similar: 35 patients were treated with the FOLFIRINOX regimen and 21 patients with Gemcitabine Nab-Paclitaxel. The number of patients undergoing surgery was 14 in the FFN group (40%) and six in the GemNab group (28.6%). The median Disease-Free Survival (DFS) was 77.10 weeks in the FFN group and 58.65 weeks in the Gem Nab group (p = 0.625), while the median PFS in the unresected group was 49.4 weeks in the FFN group and 30.9 in the GemNab group (p = 0.0029, 95% CI 0.138–0.862, HR 0.345). The overall survival (OS) in the resected population needs a longer follow up to be completely assessed, while the median overall survival (mOS) in the FFN group was 72.10 weeks and 53.30 weeks for the GemNab group (p = 0.06) in the unresected population. Surgery is a valuable option for LAPC patients and it is able to induce a relevant survival advantage. FOLFIRINOX and Gem-NabPaclitaxel should be offered as first options to pancreatic cancer patients in the locally advanced setting